We have identified a function of CD44 in concert with CXCL12/CXCR4 in the resistance of AML cells to venetoclax, which, in combination with hypomethylating agents or low-dose cytarabine, may offer hope to patients deemed unfit for classical chemotherapy against AML. The gene discussed is CD44; the disease is acute myeloid leukemia.